2025-11-17T20:59:01-06:00 2024-12-31 873231666 PKF O'CONNOR DAVIES ADVISORY LLC 500 MAMARONECK AVENUE SUITE 301 HARRISON NY 105281633 990 2024-01-01 203382296 INTERNATIONAL BIOMEDICAL RESEARCH ALLIANCE INTE 7714441353 2001 L ST NW 500 WASHINGTON DC 20036 STEPHEN M MCLEAN CHAIRMAN 7714441353 2025-11-17 1 1 X EVA MRUK P00543254 9143818900 2025-11-17 2024 2025-03-06 01:10:19Z X AUSTIN SWAFFORD 2001 L ST NW 500 WASHINGTON DC 20036 292601 0 X WWW.BIOMEDALLIANCE.ORG X 2005 DC WE EMPOWER PROMISING BIOMEDICAL RESEARCHERS THROUGH: A) FINANCIALLY SUPPORTING INTERNATIONAL COLLABORATIVE RESEARCH B) PROVIDING PROFESSIONAL & CAREER DEVELOPMENT C) CREATING A WELL-RESOURCED NETWORKING PLATFORM 16 16 2 20 0 0 204411 278773 0 0 468 767 1319 13061 206198 292601 50984 48383 0 0 163675 254407 0 0 51455 162132 244642 376791 547432 -170593 -254831 324062 114478 2566 45301 321496 69177 X OUR MISSION IS TO INVEST IN AND ACCELERATE THE DEVELOPMENT OF THE MOST PROMISING FUTURE LEADERS IN BIOMEDICAL RESEARCH WITH GLOBAL IMPACT. 0 0 355508 48383 3875 THE INTERNATIONAL BIOMEDICAL RESEARCH ALLIANCE ADVANCES THE TRAINING AND CAREER DEVELOPMENT OF FUTURE LEADERS IN BIOMEDICAL RESEARCH THROUGH SCHOLARSHIPS, MENTORSHIP, AND PROFESSIONAL DEVELOPMENT PROGRAMS. IN 2024, IBRA SUPPORTED MORE THAN 40 ACTIVE PARTICIPANTS WITH RESEARCH AND LEADERSHIP TRAINING, DELIVERED OVER 30 DAYS OF PROFESSIONAL DEVELOPMENT PROGRAMMING, AND ENGAGED NEARLY 400 ALUMNI AND CURRENT SCHOLARS REPRESENTING MORE THAN 185 UNIVERSITIES ACROSS 9 COUNTRIES.IBRA EXPANDED ITS PROGRAMMING IN 2024 TO STRENGTHEN PROFESSIONAL NETWORKS AND LEADERSHIP PATHWAYS FOR EARLY-CAREER RESEARCHERS. ACTIVITIES INCLUDED ALUMNI MENTORSHIP INITIATIVES, COLLABORATIVE WORKSHOPS, AND SECTOR-SPANNING CAREER DEVELOPMENT PROGRAMS CONNECTING ACADEMIA, INDUSTRY, AND INVESTMENT COMMUNITIES. THESE EFFORTS BROADENED IBRA'S IMPACT BEYOND DOCTORAL TRAINING, SUPPORTING A GLOBAL COMMUNITY OF BIOMEDICAL PROFESSIONALS COMMITTED TO ADVANCING TREATMENTS AND CURES FOR HUMAN DISEASE.IBRA PROVIDES LEADERSHIP DEVELOPMENT AND PROFESSIONAL SKILLS TRAINING TO STRENGTHEN THE CAPACITY OF EARLY-CAREER BIOMEDICAL RESEARCHERS. IN 2024, THE ORGANIZATION DELIVERED OVER A DOZEN STRUCTURED WORKSHOPS AND TRAINING EVENTS COVERING TOPICS SUCH AS RESEARCH ETHICS, SCIENTIFIC COMMUNICATION, ENTREPRENEURSHIP, AND TRANSLATIONAL MEDICINE, DIRECTLY BENEFITING BOTH CURRENT SCHOLARS AND ALUMNI.IBRA FOSTERS A GLOBAL BIOMEDICAL RESEARCH COMMUNITY THROUGH ALUMNI ENGAGEMENT AND COLLABORATIVE NETWORKING PROGRAMS. IN 2024, IBRA SUPPORTED MENTORING RELATIONSHIPS ACROSS ITS NETWORK OF NEARLY 400 ALUMNI AND FACILITATED PROFESSIONAL CONNECTIONS SPANNING ACADEMIA, INDUSTRY, AND INVESTMENT SECTORS, BROADENING OPPORTUNITIES FOR COLLABORATION AND CAREER ADVANCEMENT. 355508 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 2 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 0 0 X AUSTIN SWAFFORD 7714441353 2001 L ST NW 500 WASHINGTON DC 20036 STEPHEN M MCLEAN CHAIRMAN 6.25 X X 0 0 0 KATHRYN ZOON PHD VICE CHAIR 6.25 X X 0 0 0 ALAN K JONES TREASURER 3.75 X X 0 0 0 BRIAN ATWOOD DIRECTOR 1.25 X 0 0 0 BRIAN BRILLE DIRECTOR 2.50 X 0 0 0 JEREMY P GOLDBERG DIRECTOR 2.50 X 0 0 0 SABRINA HEMAN-ACKAH MD PHD ALUMNI DIRECTOR 1.25 X 0 0 0 ADAM KNIGHT PHD ALUMNI DIRECTOR 0.62 X 0 0 0 SCOTT KOENIG MD DIRECTOR 2.50 X 0 0 0 RALPH KORPMAN MD DIRECTOR 1.25 X 0 0 0 JUSTIN LATHIA PHD ALUMNI DIRECTOR 1.25 X 0 0 0 GEOFFREY LYNN DIRECTOR 5.00 X 0 0 0 JOHN NIEDERHUBER MD DIRECTOR 1.25 X 0 0 0 RONALD RICHARD DIRECTOR 2.50 X 0 0 0 PENELOPE ROSE DIRECTOR, THRU OCT 2024 0.50 X 0 0 0 CORALIE VIOLLET ALUMNI DIRECTOR 2.50 X 0 0 0 RUPERT VESSEY BM BCH DPHIL DIRECTOR 2.50 X 0 0 0 AUSTIN SWAFFORD PHD PRESIDENT 40.00 X 140000 0 0 140000 0 0 1 0 0 0 0 278773 47567 278773 767 767 REIMBURSEMENTS 900099 9186 9186 COLLOQUIUM 900099 3875 3875 13061 292601 3875 0 9953 48383 48383 140000 56000 56000 28000 76930 30772 30772 15386 10772 4309 4309 2154 26705 10682 10682 5341 185 185 12130 12130 2550 2550 574 574 8440 8440 10357 10357 7890 5546 2344 82744 82744 2070 2070 AWARDS & DEVELOPMENT 43682 43052 630 SCHOLAR RECRUITMENT 37186 37186 SCHOLAR CAREER DEV. 36834 36834 547432 355508 140469 51455 124504 90985 199558 23493 324062 114478 2566 45301 2566 45301 X 184624 39726 136872 29451 321496 69177 324062 114478 -254831 2512 0 X X 0 0 0 X 285929 303126 1007674 204411 278773 2079913 285929 303126 1007674 204411 278773 2079913 617177 1462736 668 134 124 468 767 2161 1101 5288 1319 13061 20769 2102843 10920 0.69560 0.67390 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: REIMBURSEMENTS - 2021 AMOUNT: $ 1,101. 2022 AMOUNT: $ 5,288. 2023 AMOUNT: $ 1,319. 2024 AMOUNT: $ 9,186. COLLOQUIUM - 2024 AMOUNT: $ 3,875. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED EUROPE 0 0 PROGRAM SERVICES RESEARCH WORKSHOPS & EVENTS EXPENDITURES 40678 EUROPE 0 0 PROGRAM SERVICES SCHOLAR CAREER DEVELOPMENT 1597 0 0 0 0 0 0 42275 0 42275 0 0 0 0 0 0 PART I, LINE 3: THE ORGANIZATION USES THE ACCRUAL METHOD OF ACCOUNTING TO ACCOUNT FOR EXPENDITURES. 1 SCHOLARSHIPS 10 48383 PART I, LINE 2: GRANT AGREEMENTS INCLUDE A BUDGET DETAILING INTENDED USE OF THE FUNDS. GRANT RECIPIENTS ARE REQUIRED TO MAINTAIN RECORDS OF RECEIPTS AND SUBMIT WRITTEN REPORTS TO THE ORGANIZATION. THE WRITTEN REPORT INCLUDES A NARRATIVE ACCOUNT AND A FINANCIAL ACCOUNT OF WHAT IS ACCOMPLISHED BY THE EXPENDITURE OF THE GRANT FUNDS. X 1 47567 AVG. SELLING PRICE 0 0 0 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS IN COLUMN (B). FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S PRESIDENT, CHAIRMAN, TREASURER, AND CHAIR AND VICE CHAIR OF THE DEVELOPMENT & FINANCE COMMITTEE RECEIVE A COMPLETE COPY OF FORM 990 FOR REVIEW AND COMMENT PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. SUBSEQUENT TO FILING, ALL MEMBERS OF THE BOARD OF DIRECTORS RECEIVE AN ELECTRONIC COPY (WITH A PAPER COPY AVAILABLE UPON REQUEST) AT A MEETING OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C COMMITTED TO MAINTAINING THE HIGHEST LEVEL OF ETHICAL STANDARDS, CONDUCT, AND PRACTICES, THE ORGANIZATION ABIDES BY A CONFLICTS OF INTEREST POLICY AND PROCEDURE THAT GOVERNS THE OVERSIGHT OF MATTERS IN WHICH DIRECTORS, OFFICERS AND KEY EMPLOYEES MAY HAVE A CONFLICT OF INTEREST. AFTER DISCLOSURE OF A FINANCIAL INTEREST AND REVIEW OF ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INDIVIDUAL, THE FOLLOWING STEPS ARE UNDERTAKEN: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR NOMINATING & CORPORATE GOVERNANCE COMMITTEE MEETING, BUT AFTER THE PRESENTATION, THE INDIVIDUAL SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT INVOLVING THE POSSIBLE CONFLICT OF INTEREST. B. IF APPROPRIATE, THE BOARD OR THE NOMINATING & CORPORATE GOVERNANCE COMMITTEE MAY APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR NOMINATING & CORPORATE GOVERNANCE COMMITTEE SHALL DETERMINE WHETHER THE ORGANIZATION CAN OBTAIN, WITH REASONABLE EFFORTS, A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY POSSIBLE UNDER CIRCUMSTANCES NOT PRODUCING A CONFLICT OF INTEREST, THE BOARD OR NOMINATING & CORPORATE GOVERNANCE COMMITTEE SHALL DETERMINE, BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS, WHETHER THE TRANSACTION OR ARRANGEMENT IS IN IBRA'S BEST INTEREST, FOR ITS OWN BENEFIT, AND WHETHER IT IS FAIR AND REASONABLE. IN CONFORMITY WITH THE ABOVE DETERMINATION, IT SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT. THE NOMINATING & CORPORATE GOVERNANCE COMMITTEE SHALL INTERPRET AND OVERSEE THE IMPLEMENTATION OF THE CONFLICTS OF INTEREST POLICY, REVIEW AND SUGGEST MODIFICATIONS TO IMPROVE THE CONFLICTS OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15A THE NOMINATING & CORPORATE GOVERNANCE COMMITTEE MEMBERS DETERMINE THE SCOPE OF DUTIES AND RELATED COMPENSATION BASED ON MARKET RATE COMPARISONS INCLUDING ONLINE REPOSITORIES OF SALARY INFORMATION (LINKEDIN, GLASSDOOR, ETC.) AND THE COMPENSATION PROVIDED TO THE EXECUTIVE DIRECTOR OF SIMILARLY SIZED ORGANIZATIONS THROUGH MANUAL REVIEW OF PUBLIC FORM 990S. THESE RECOMMENDATIONS ARE THEN REFERRED TO THE FULL BOARD OF DIRECTORS FOR APPROVAL, AND THIS PROCESS WAS LAST UNDERTAKEN IN 2023. DOCUMENTATION OF THESE DISCUSSIONS WAS MADE IN THE MINUTES OF THE SUBCOMMITTEE AND FULL BOARD MEETINGS. COMPENSATION FOR OFFICERS AND KEY EMPLOYEES IS REVIEWED AND APPROVED BY INDEPENDENT MEMBERS OF THE BOARD. THE PROCESS INCLUDES REVIEW OF COMPARABLE COMPENSATION DATA FROM SIMILARLY SITUATED NONPROFIT ORGANIZATIONS AND IS DOCUMENTED IN THE BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY AVAILABLE TO THE PUBLIC VIA WEBSITE LINKS OR DIRECTLY VIA EMAIL UPON REQUEST. FORM 990, PART XII, LINE 2C THE DEVELOPMENT AND FINANCE COMMITTEE IS RESPONSIBLE FOR OVERSIGHT OF THE AUDIT, REVIEW, OR COMPILATION OF ITS FINANCIAL STATEMENTS AND THE SELECTION OF AN INDEPENDENT ACCOUNTANT WHERE REQUIRED.